Acumen Pharmaceuticals Inc (ABOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Acumen Pharmaceuticals Inc (ABOS) has a cash flow conversion efficiency ratio of -0.276x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.13 Million) by net assets ($87.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Acumen Pharmaceuticals Inc (ABOS) total market value for the company's overall valuation and market capitalisation.
Acumen Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Acumen Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Acumen Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acumen Pharmaceuticals Inc ranked by their cash flow conversion efficiency. See ABOS operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Madhya Bharat Agro Products Limited
NSE:MBAPL
|
0.245x |
|
Inversiones Doalca SOCIMI SA
MC:YDOA
|
0.127x |
|
Daol Investment & Securities
KO:030210
|
0.303x |
|
Ihlas Haber Ajansi AS
IS:IHAAS
|
-0.228x |
|
Casa de Bolsa Finamex S.A.B. de C.V
MX:FINAMEXO
|
0.039x |
|
GPT Infraprojects Limited
NSE:GPTINFRA
|
0.021x |
|
Plenitude Bhd
KLSE:5075
|
0.038x |
|
Pondy Oxides & Chemicals Limited
NSE:POCL
|
0.171x |
Annual Cash Flow Conversion Efficiency for Acumen Pharmaceuticals Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Acumen Pharmaceuticals Inc from 2019 to 2025. View ABOS live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $70.43 Million | $-115.54 Million | -1.640x | -245.95% |
| 2024-12-31 | $181.82 Million | $-86.22 Million | -0.474x | -193.97% |
| 2023-12-31 | $266.97 Million | $-43.06 Million | -0.161x | +13.38% |
| 2022-12-31 | $188.78 Million | $-35.15 Million | -0.186x | -133.47% |
| 2021-12-31 | $225.18 Million | $-17.96 Million | -0.080x | -119.90% |
| 2020-12-31 | $-18.59 Million | $-7.45 Million | 0.401x | -32.88% |
| 2019-12-31 | $-11.42 Million | $-6.82 Million | 0.597x | -- |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement… Read more